ÂÜÀòÂÒÂ×

Dr. Dudley has over 30 years of experience in anti-infective R&D and commercialization. In 2018, he led the Series A financing for Qpex and the acquisition of the preclinical programs from The Medicines Company. He has overseen R&D and regulatory approval of multiple anti-infectives, including most recently vaborbactam which progressed from discovery to FDA approval in < 8 years. He was CSO of Rempex when it was acquired by the Medicines Company (MDCO), where he remained as co-leader of the Infectious Disease Business Unit.

Mike has led negotiations for multiple public-private partnerships (e.g., BARDA; Innovative Medicines Initiative) for over $190 million to advance the development of antimicrobial agents in the US and Europe. Before Rempex/MDCO, he held leadership positions of increasing responsibility at Mpex, Diversa, and Microcide. Prior to his career in industry, he held academic appointments at the University of Rhode Island College of Pharmacy and Brown University School of Medicine. He has published over 140 scientific papers/book chapters on the evaluation and clinical use of antiinfectives. He completed undergraduate work at Pepperdine University, his PharmD and residency from the University of California San Francisco (UCSF), and a fellowship in infectious diseases at Hartford Hospital.